论文部分内容阅读
目的 探讨肺表面活性物质(PS)在治疗新生儿肺透明膜病(HMD)Ⅱ级的疗效。方法 对60例经X线胸片检查为HMDⅡ级的患儿。30例6小时内应用肺表面活性物质;30例无应用肺表面活性物质,通过用药后20小时(或约生后24小时)X线胸片的诊断与上呼吸机时间、并发症的比较分析,评价肺表面活性物质治疗肺透明膜病的疗效。结果 两组病例在生后24小时的X线胸片,平均上呼吸机时间,住院天数、死亡率,有显著性差异,P<0.05。并发症方面,肺炎发生率显著性差异,P<0.05。结论 PS在治疗HMD中可以明显改善肺透明膜病的转归,减少并发症,降低死亡率。
Objective To investigate the efficacy of pulmonary surfactant (PS) in the treatment of neonatal hyaline membrane disease (HMD) Ⅱ. Methods Sixty children with HMD grade Ⅱ were examined by X-ray. 30 cases of pulmonary surfactant within 6 hours; 30 cases without pulmonary surfactant, through the diagnosis of chest X-ray 20 hours after treatment (or after about 24 hours) and ventilator time, complication analysis , Evaluate the efficacy of pulmonary surfactant in the treatment of hyaline membrane disease. Results There were significant differences in X-ray, average respirator time, hospitalization days and mortality between the two groups at 24 hours after birth (P <0.05). Complications, the incidence of pneumonia was significantly different, P <0.05. Conclusion PS in the treatment of HMD can significantly improve the outcome of hyaline membrane disease, reduce complications and reduce mortality.